Physician profile
Jonathan Cone
NPI 1710204706
$12,188.30
in general payments reported to CMS, 2019-2025
28 companies · $3,872 in 2025
The $3,872 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $287 · 2021: $805 · 2022: $1,313 · 2023: $2,656 · 2024: $3,038 · 2025: $3,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,546 · Travel and Lodging: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,545.52 |
| Travel and Lodging | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,731.84 | 2020-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,887.82 | 2020-2025 | Sunlenca, Biktarvy |
| Merck Sharp & Dohme LLC | $728.51 | 2020-2025 | Pifeltro, Gardasil 9, Capvaxive |
| Janssen Biotech, INC. | $650.34 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $479.17 | 2021-2025 | Mytesi |
| Theratechnologies INC. | $467.67 | 2023-2025 | Trogarzo, Egrifta |
| Emd Serono, INC. | $342.02 | 2022-2025 | Serostim |
| Exact Sciences Corporation | $297.65 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $287.65 | 2019-2024 | Pediarix, Bexsero, Shingrix |
| Pfizer INC. | $255.96 | 2019-2024 | |
| Janssen Products, Lp | $224.16 | 2021-2022 | |
| Abbvie INC. | $159.82 | 2021-2025 | Mavyret |
| Indivior INC. | $131.77 | 2022-2025 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $114.71 | 2023-2025 | Ingrezza |
| Lilly USA, LLC | $62.68 | 2024-2025 | Mounjaro, Zepbound |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $58.76 | 2022 | |
| Cranial Technologies, INC | $46.78 | 2019 | |
| Abbott Laboratories | $46.12 | 2024 | Proclaim, Eterna |
| Seqirus USA INC | $41.17 | 2024-2025 | Flucelvax, Fluad |
| Dynavax Technologies Corporation | $31.34 | 2024 | Heplisav-B |
| Dexcom, INC. | $24.10 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $22.04 | 2023 | Invega Sustenna, Invega Trinza |
| Xeris Pharmaceuticals, INC. | $20.10 | 2025 | Gvoke Hypopen |
| Novo Nordisk INC | $18.55 | 2025 | Wegovy |
| Braeburn INC. | $18.20 | 2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $15.17 | 2022 | |
| Antares Pharma, INC. | $12.92 | 2023 | Xyosted, Nocdurna, Tlando |
| Coopersurgical, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.